Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt

Survival and 30-days Hospital Outcome in Hospitalized COVID-19 Patients in Upper Egypt: Multi-center Study

Through history, there have been plenty of pandemics however; the social response to corona virus disease (COVID-19) is unparalleled. It is assessed that almost four billion individuals are living in social segregation during this mother of all pandemics.

Initially described in China in December 2019, severe acute respiratory syndrome caused by corona virus 2 (SARS-CoV-2) has spread all over the world and by 18th July 2020- there was an emergent figure of 13,824,739 confirmed cases and 591.666 losses reported to the WHO. To date, Egypt reported slightly over 82,000 confirmed COVID-19 cases with 3858 deaths. The new pandemic is injuring not only health organizations of several countries but also the financial prudence universal.

Defining the clinical features and associated outcomes of patients diagnosed with coronavirus disease (COVID-19) is fundamental to improving our understanding and adequate management of this illness. Several articles have recently been published, describing the clinical features and outcomes of retrospective individuals with COVID-19

Study Overview

• Status: Completed
• Conditions: Covid19; SARS-CoV-2; Coronavirus Disease
• Intervention / Treatment: Other: Kaplan Meier analysis

• Study Type: Observational
• Enrollment (Actual): 1064

Contacts and Locations

Study Locations

• Egypt
  • Assiut, Egypt, 71515
    • Aliae Mohamed-Hussein
  • Assiut, Egypt, 71111
    • AssiutU

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 36 years to 63 years (Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All cases had confirmed COVID-19 infection (based on PCR, chest HRCT, CBC, CRP, Ferritin levels) and received standardized treatment protocols of Ministry of Health and Population based on disease severity.

Description

Inclusion Criteria:

• This study included 1064 patients consecutively admitted to isolation hospitals in Upper Egypt during the period from 22 March to 23 June 2020

Exclusion Criteria:

• only hospitalized confirmed cases of COVID-19 were included.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
number of co-morbidities in hospitalized patients with COVID-19	Determinants of survival in studied covid-19 patients admitted to hospitals	one month
causes of ICU admission	Determinants of ICU admission in hospitalized patients with COVID-19	one month

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Principal Investigator: Aliae Mohamed-Hussein, MD, Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2020
• Primary Completion (Actual): May 1, 2020
• Study Completion (Actual): July 1, 2020

Study Registration Dates

• First Submitted: July 24, 2020
• First Submitted That Met QC Criteria: July 25, 2020
• First Posted (Actual): July 28, 2020

Study Record Updates

• Last Update Posted (Actual): July 28, 2020
• Last Update Submitted That Met QC Criteria: July 25, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: Survival; COVID-19; outcome; 30- Days Hospital outcome
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: AssiutU17

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No